C. Lamers

发表

Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors

E. Wiemer, N. Naus, R. Mathijssen, 2014, Clinical Cancer Research.

Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

S. Sleijfer, M. D. den Bakker, C. Lamers, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Inhibition of bispecific monoclonal antibody (bsAb)‐targeted cytolysis by human anti‐mouse antibodies in ovarian carcinoma patients treated with bsAb‐targeted activated T‐lymphocytes

C. Lamers, J. Gratama, G. Stoter, 1995, International journal of cancer.

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS

J. Aerts, A. Langerak, R. Hendriks, 2018, Front. Immunol..

Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis

C. Lamers, J. Gratama, T. Mondria, 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

Activation of the immune system of cancer patients by continuous i.v. recombinant IL‐2 (rIL‐2) therapy is dependent on dose and schedule of rIL‐2

C. Lamers, J. Gratama, G. Stoter, 1993, Clinical and experimental immunology.

Circulating endothelial cells in oncology: pitfalls and promises

S. Sleijfer, C. Lamers, M. Strijbos, 2008, British Journal of Cancer.

The reaction of the immune system of fish to vaccination

C. Lamers, 1985 .

T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.

S. Sleijfer, C. Lamers, P. van Elzakker, 2014, Human gene therapy methods.

Chimeric antigen receptors for T-cell based therapy.

C. Lamers, H. Abken, R. Debets, 2012, Methods in molecular biology.

Retroviral vectors for clinical immunogene therapy are stable for up to 9 years

S. Sleijfer, C. Lamers, J. Gratama, 2008, Cancer Gene Therapy.

T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies

S. Sleijfer, C. Lamers, R. Debets, 2010, Expert opinion on biological therapy.

Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo

S. Sleijfer, C. Lamers, J. Gratama, 2007, Cancer Immunology, Immunotherapy.

Modulation of immune parameters in patients with metastatic renal‐cell cancer receiving combination immunotherapy (IL‐2, IFNα and autologous IL‐2‐activated lymphocytes)

C. Lamers, J. Gratama, P. Schmitz, 1996, International journal of cancer.

Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer

C. Lamers, R. Debets, R. Bolhuis, 2002, Cancer Gene Therapy.

Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.

A. Eggermont, C. Lamers, J. Gratama, 1995, Journal of the National Cancer Institute.

Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re‐targeted by a bi‐specific monoclonal antibody

C. Lamers, J. Gratama, G. Stoter, 1997, International journal of cancer.

Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.

A. Lanzavecchia, A. Eggermont, C. Lamers, 1992, International journal of cancer. Supplement = Journal international du cancer. Supplement.

Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.

V. Zurawski, C. Lamers, R. Bolhuis, 1997, Journal of immunotherapy.

ACTIVATION AND EXPANSION OF HUNAN CYTOTOXIC T LYMPHOCYTES IN HOLLOW FIBER BIOREACTORS

C. Lamers, J. Gratama, R. Bolhuis, 1994 .

Combination Immunotherapy with Interleukin-2 (IL-2), Alpha-Interferon (αIFN), and Autologous IL-2-Activated Lymphocytes (LAK) in Metastatic Renal Cell Cancer

A. Eggermont, C. Lamers, J. Gratama, 1995 .

Interleukin-2

A. Eggermont, C. Lamers, G. Stoter, 1990 .

TCRGene Transfer : MAGE-C 2 / HLA-A 2 andMAGE-A 3 / HLA-DP 4 Epitopes as Melanoma-Specific Immune Targets

B. Lambrecht, M. Broertjes, P. Coulie, 2012 .

TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets

B. Lambrecht, M. Broertjes, P. Coulie, 2012, Clinical & developmental immunology.

Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells.

S. Sleijfer, C. Lamers, J. Gratama, 2013, Cytotherapy.

Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials

S. Rosenberg, R. Morgan, C. Lamers, 2010, Clinical Cancer Research.

Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer

C. Lamers, J. Gratama, R. Debets, 2006, Cancer Gene Therapy.

Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.

S. Sleijfer, C. Lamers, J. Gratama, 2006, Cytotherapy.

Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression.

C. Lamers, J. Gratama, G. Stoter, 2005, Human gene therapy.

TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.

C. Lamers, A. Mondino, R. Debets, 2010, Molecular immunology.

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study

S. Sleijfer, J. Blay, F. Collin, 2012, British Journal of Cancer.

Structural and functional aspects of the spleen in bony fish.

C. Lamers, J. Rombout, W. B. Van Muiswinkel, 1991, Research in immunology.

Enteroendocrine APUD cells in the digestive tract of larval Barbus conchonius (Teleostei, Cyprinidae).

C. Lamers, J. Rombout, J. Hanstede, 1978, Journal of embryology and experimental morphology.

Immunologic Analysis of a Phase I/II Study of Vaccination with MAGE-3 Protein Combined with the AS02B Adjuvant in Patients with MAGE-3-Positive Tumors

C. Lamers, G. Stoter, U. Keilholz, 2004, Journal of immunotherapy.

MAGE-C2–Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses

S. Sleijfer, P. Coulie, C. Lamers, 2016, The Journal of Immunology.

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer

S. H. van der Burg, R. Dummer, M. Welters, 2020, Journal for ImmunoTherapy of Cancer.

Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction

P. Siersema, C. Lamers, A. van der Gaast, 2015, Journal of cachexia, sarcopenia and muscle.

Optimization of culture conditions for activation and large‐scale expansion of human T lymphocytes for bispecific antibody‐directed cellular immunotherapy

J. Bénard, C. Lamers, G. Stoter, 1992, International journal of cancer.

Preparation for a phase I/II study using autologous gene modified T lymphocytes for treatment of metastatic renal cancer patients.

C. Lamers, J. Gratama, M. Weijtens, 1998, Advances in experimental medicine and biology.

CD4+ T-cell alloreactivity after haploidentical hematopoietic stem cell transplantation

C. Lamers, J. Cornelissen, E. Braakman, 2020, Haematologica.

Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies.

P. S. Sillevis Smitt, C. Lamers, J. Gratama, 2012, Neuro-oncology.

The fate of intraperitoneally injected carbon particles in cyprinid fish

C. Lamers, H. Parmentier, 1985, Cell and Tissue Research.

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies

R. Vernhout, A. Kleijn, M. Lamfers, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Convection enhanced delivery of the oncolytic adenovirus Delta24-RGD in patients with recurrent GBM: A phase I clinical trial including correlative studies

A. Kleijn, M. Lamfers, F. Lang, 2022 .

Interleukin 12 induces activation of fibrinolysis and coagulation in humans

C. Hack, M. Schuler, A. Sparreboom, 2001, British journal of haematology.

Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield.

S. Sleijfer, C. Lamers, J. Gratama, 2008, Cytotherapy.

Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.

A. Sparreboom, C. Lamers, C. Huber, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Intraperitoneal therapy of ovarian cancer with retargeted lymphocytes by bispecific monoclonal antibodies and interleukin-2

A. Eggermont, A. Eggermont, C. Lamers, 1995, Acta Chirurgica Austriaca.

Impaired thymopoiesis predicts for a high risk of severe infections after reduced intensity conditioning without anti-thymocyte globulin in double umbilical cord blood transplantation

B. van der Holt, C. Lamers, J. Cornelissen, 2018, Bone Marrow Transplantation.

High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer.

A. Eggermont, A. Eggermont, C. Lamers, 1997, Journal of immunotherapy.

No evidence for the presence of HuD-specific T cells in the cerebrospinal fluid of patients with Huassociated paraneoplastic neurological syndromes

P. S. Sillevis Smitt, C. Lamers, J. Gratama, 2009, Journal of Neurology.

Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program

A. Gratwohl, D. Niederwieser, F. Lanza, 2012, Bone Marrow Transplantation.

JACIE celebrates its 10-year anniversary with the demonstration of improved clinical outcome.

A. Gratwohl, D. Niederwieser, F. Lanza, 2011, Cytotherapy.

Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection.

C. Tournay, C. Lamers, J. Gratama, 2001, Blood.

Antigen localization in the lymphoid organs of carp (Cyprinus carpio)

M. Haas, C. Lamers, C. H. J. Lamers, 2004, Cell and Tissue Research.

Uptake and transport of intact macromolecules in the intestinal epithelium of carp (Cyprinus carpio L.) and the possible immunological implications

C. Lamers, J. Rombout, J. J. Taverne-Thiele, 2004, Cell and Tissue Research.

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu

S. Sleijfer, R. Mathijssen, C. Lamers, 2013, Front. Immunol..

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

S. Sleijfer, C. Lamers, J. Gratama, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.

Egbert Oosterwijk, Stefan Sleijfer, S. Sleijfer, 2011, Blood.

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

C. Lamers, P. Mulders, E. Oosterwijk, 2004, British Journal of Cancer.

T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk

T. Blankenstein, C. Lamers, R. Debets, 2017, Clinical Cancer Research.

Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes

S. Sleijfer, M. Smid, C. Lamers, 2020, Journal for ImmunoTherapy of Cancer.

T-Cell Engineering and Expansion — GMP Issues

Cor Lamers, Ryan D. Guest, R. Guest, 2014 .

Gibbon Ape Leukemia Virus Poorly Replicates in Primary Human T Lymphocytes: Implications for Safety Testing of Primary Human T Lymphocytes Transduced With GALV-pseudotyped Vectors

C. Lamers, J. Gratama, P. van Elzakker, 2009, Journal of immunotherapy.

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview.

S. Sleijfer, C. Lamers, J. Gratama, 2016, Biochemical Society transactions.

Immunization of carp (Cyprinus carpio) with a Vibrio anguillarum bacterin: indications for a common mucosal immune system.

C. Lamers, E. Egberts, L. Blok, 1986, Developmental and comparative immunology.

Natural and Acquired Agglutinins to Aeromonas hydrophila in Carp (Cyprinus carpio)

C. Lamers, W. V. Muiswinkel, 1986 .

The fate of intraperitoneally carbon particles in cyprinid fish

C. Lamers, H. Parmentier, 1985 .

Humoral response and memory formation in carp after injection of Aeromonas hydrophila bacterin.

C. Lamers, M. de Haas, W. B. Van Muiswinkel, 1985, Developmental and comparative immunology.

Fish immunology and fish health

C. Lamers, E. Egberts, J. Loon, 1985 .

Histophysiology of a primary immune response against Aeromonas hydrophila in carp (Cyprinus carpio L.).

C. Lamers, 1986 .

Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation

C. Lamers, R. Bolhuis, J. Cornelissen, 1999, Bone Marrow Transplantation.

T-lymphocyte reconstitution following rigorously T-cell-depleted versus unmodified autologous stem cell transplants

C. Lamers, J. Gratama, B. Löwenberg, 2006, Bone Marrow Transplantation.

CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab

S. Sleijfer, J. Aerts, R. Mathijssen, 2019, Journal of Immunotherapy for Cancer.

A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.

C. Lamers, P. Mulders, P. D. De Mulder, 2003, Folia biologica.

Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.

M. Schuler, C. Lamers, G. Stoter, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A10 Cancer immunity

C. Lamers, J. Gratama, R. Debets, 2011 .

CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation.

J. Falkenburg, C. Lamers, J. Gratama, 2016, Blood.

Adoptive T-cell therapy: a need for standard immune monitoring.

S. Sleijfer, C. Lamers, R. Debets, 2015, Immunotherapy.

Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours.

J. Verweij, C. Lamers, M. D. de Jonge, 2009, European Journal of Cancer.

Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant

C. Hack, M. Schuler, A. Sparreboom, 2004, Cancer Immunology, Immunotherapy.

Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-γ, tumor necrosis factor-α, IL-6, and IL-8 responses

A. Sparreboom, C. Lamers, C. Huber, 2003 .

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients

S. Sleijfer, C. Lamers, S. V. van Steenbergen, 2016, Front. Immunol..

Genetically modified T lymphocytes: more than just direct effectors.

C. Lamers, R. Debets, 2013, Immunotherapy.

Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells.

S. Sleijfer, C. Lamers, S. V. van Steenbergen, 2016, Clinical immunology.

A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.

J. Verweij, C. Lamers, P. Schmitz, 1998, British Journal of Cancer.

Large-scale production of natural cytokines during activation and expansion of human T lymphocytes in hollow fiber bioreactor cultures.

C. Lamers, J. Gratama, R. Bolhuis, 1999, Journal of immunotherapy.

An experimental study on neural crest migration in Barbus conchonius (Cyprinidae, Teleostei), with special reference to the origin of the enteroendocrine cells.

C. Lamers, J. Rombout, L. Timmermans, 1981, Journal of embryology and experimental morphology.

Double Umbilical Cord Blood Transplantation in High-Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance

B. van der Holt, C. Lamers, C. V. van Bergen, 2019, HemaSphere.

Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage

S. Sleijfer, C. Lamers, M. Strijbos, 2008, Thrombosis and Haemostasis.

Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors

S. Sleijfer, A. Jager, C. Lamers, 2012, Cancer.

Graft predominance after double umbilical cord blood transplantation: a review.

C. Lamers, J. Cornelissen, Burak Kalin, 2017, Stem Cell Investigation.

Levels of circulating endothelial cells in normotensive and severe preeclamptic pregnancies

C. Lamers, M. Strijbos, J. Gratama, 2010, Cytometry. Part B, Clinical cytometry.

mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells

S. Sleijfer, C. Lamers, M. Strijbos, 2010, Thrombosis and Haemostasis.

Quantification of Circulating Endothelial Cells by Flow Cytometry

S. Sleijfer, C. Lamers, J. Gratama, 2009, Clinical Cancer Research.

Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.

S. Sleijfer, C. Lamers, J. Gratama, 2004, Journal of biological regulators and homeostatic agents.